TP53 and astrocytoma (excluding glioblastoma): This diverged from IDH1/2-mutant astrocytoma (28.8% of cases demonstrating cooccurrence, 0.5% cell cycle pathway only, 55.1% p53 pathway only) and IDH1/2-mutant oligodendroglioma (7.9% cooccurrence, 4.3% cell cycle pathway only, 7.5% p53 pathway only).